TY  - GEN
AU  - Bang,Yung-Jue
AU  - Im,Seock-Ah
AU  - Lee,Keun-Wook
AU  - Cho,Jae Yong
AU  - Song,Eun-Kee
AU  - Lee,Kyung Hee
AU  - Kim,Yeul Hong
AU  - Park,Joon Oh
AU  - Chun,Hoo Geun
AU  - Zang,Dae Young
AU  - Fielding,Anitra
AU  - Rowbottom,Jacqui
AU  - Hodgson,Darren
AU  - O'Connor,Mark J
AU  - Yin,Xiaolu
AU  - Kim,Woo Ho
TI  - Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
SN  - 1527-7755
PY  - 2016///0418
KW  - Adenocarcinoma
KW  - classification
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Ataxia Telangiectasia Mutated Proteins
KW  - blood
KW  - Biomarkers, Tumor
KW  - Biopsy, Needle
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunohistochemistry
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Paclitaxel
KW  - Phthalazines
KW  - Piperazines
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Stomach Neoplasms
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2014.60.0320
ER  -